8-K: Summit Therapeutics Presents Promising Ivonescimab Data

Summit Therapeutics announced new Phase II data for ivonescimab in metastatic colorectal cancer and positive Phase III results in squamous NSCLC.

Summary

• Summit Therapeutics presented new interim results from the global Phase II AK112-206 study of ivonescimab combined with mFOLFOX6 chemotherapy in first-line metastatic colorectal cancer (mCRC).
• The study in 49 patients showed an Objective Response Rate (ORR) of 70.8% and a Disease Control Rate (DCR) of 100.0% in evaluable patients (n=48).
• Responses were more durable with the 20 mg/kg dose of ivonescimab, with a 9-month Duration of Response (DoR) of 79.1% compared to 41.5% for the 10 mg/kg dose.
• The 9-month Progression-Free Survival (PFS) rate was 76.1% for the 20 mg/kg arm.
• Safety was comparable to historical standards, with 20.4% of patients experiencing serious treatment-related adverse events (TRAEs).
• Additionally, positive overall survival (OS) results from the Phase III HARMONi-6 trial, conducted by partner Akeso in China, were announced.
• HARMONi-6 showed ivonescimab plus chemotherapy reduced the risk of death by 34% compared to tislelizumab plus chemotherapy in first-line squamous NSCLC (Hazard Ratio 0.66).
• The 24-month OS rates were 64.7% for ivonescimab plus chemotherapy versus 48.6% for tislelizumab plus chemotherapy.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive development due to the strong clinical data presented for ivonescimab in two major oncology indications, particularly the significant OS benefit in NSCLC.

Positives

• The Phase II AK112-206 study in mCRC demonstrated a high ORR of 70.8% and a DCR of 100.0% in treatment-naïve patients.
• The 20 mg/kg dose of ivonescimab showed more durable responses, with a 9-month DoR of 79.1% and a 9-month PFS rate of 76.1%.
• The safety profile of ivonescimab in combination with chemotherapy is considered acceptable and manageable, with no new safety signals observed.
• The Phase III HARMONi-6 trial in China showed a statistically significant improvement in Overall Survival (OS) for ivonescimab plus chemotherapy compared to tislelizumab plus chemotherapy (HR 0.66, p=0.0017).
• The HARMONi-6 trial demonstrated a 34% reduction in the risk of death and improved 24-month OS rates (64.7% vs. 48.6%).
• Ivonescimab is the first agent to show a statistically significant OS benefit over an anti-PD-(L)1 antibody combined with chemotherapy in a Phase III trial in first-line NSCLC.
• The safety profile in HARMONi-6 was consistent with prior studies, with manageable treatment-related adverse events.

Negatives

• While the 9-month PFS analysis in the Phase II mCRC study is immature, the 10 mg/kg dose showed significantly less durable responses (41.5% DoR at 9 months).
• Grade 3 or higher hemorrhage events occurred in 2.6% of patients in the ivonescimab arm compared to 0.8% in the tislelizumab arm in the HARMONi-6 study.
• Treatment-related serious adverse events occurred in 41.4% of patients receiving ivonescimab plus chemotherapy in HARMONi-6, compared to 34.3% for tislelizumab plus chemotherapy.

Risks

• Ivonescimab is an investigational therapy and not approved by regulatory authorities in the US and Europe.
• The Phase II mCRC study's PFS analysis is still immature.
• There is a potential for increased risk of hemorrhage events with ivonescimab plus chemotherapy, although most VEGF-related events were Grade 1-2.
• The HARMONi-6 study was conducted in China and sponsored by Akeso, with data exclusively generated, managed, and analyzed by Akeso.

Future Outlook

Summit Therapeutics is advancing the development of ivonescimab across multiple tumor types. The company is conducting the global Phase III HARMONi-GI3 trial for first-line mCRC and has a BLA submission for ivonescimab in NSCLC with a PDUFA date of November 14, 2026. Further data readouts for HARMONi-3 (squamous NSCLC) are expected in 1H26 and 1H27.

Management Comments

• "These data add to the growing body of evidence supporting the potential of ivonescimab as a differentiated PD-1 / VEGF bispecic, and we are committed to advancing its development across multiple tumor types where we believe it may meaningfully improve patient outcomes."
• "For the first time, a Phase III clinical study has demonstrated a statistically significant overall survival benefit in front-line driver-mutation-negative non-small cell lung cancer compared to anti-PD-1 therapy in combination with chemotherapy."
• "The decision we made in December 2022 to enter into a partnership specifically with Akeso and accelerate the global clinical development plan of this potentially landscape-changing compound in ivonescimab is further validated with these groundbreaking results for patients facing high unmet medical needs."

Industry Context

StockSavvy.ai notes that the presented data for ivonescimab in both mCRC and NSCLC are significant. The ORR in mCRC is competitive with existing therapies, and the OS benefit in first-line NSCLC, particularly against another PD-1 inhibitor, addresses a critical unmet need and could position ivonescimab as a new standard of care.

Comparison to Industry Standards

• In first-line metastatic colorectal cancer (mCRC), the ORR of 70.8% with ivonescimab plus mFOLFOX6 is encouraging compared to historical performance of standard-of-care regimens combining bevacizumab with FOLFOX chemotherapy.
• In first-line squamous NSCLC, the HARMONi-6 trial demonstrated a statistically significant overall survival benefit (HR 0.66) compared to tislelizumab plus chemotherapy, a result not previously achieved in head-to-head Phase III trials against anti-PD-(L)1 inhibitors combined with chemotherapy.
• The safety profile of ivonescimab plus chemotherapy in both studies is reported as comparable to or manageable relative to established standards of care, including chemotherapy alone or in combination with anti-VEGF therapies.

Stakeholder Impact

• Shareholders: Positive clinical data may lead to increased investor confidence and potential stock price appreciation.
• Patients: Promising results offer hope for improved treatment options and outcomes in mCRC and NSCLC.
• Healthcare Providers: New data may influence treatment decisions and clinical practice guidelines.
• Partners (Akeso): Validation of the partnership and the potential of ivonescimab.

Next Steps

• Continue development of ivonescimab across multiple tumor types.
• Advance the global Phase III HARMONi-GI3 trial in first-line mCRC.
• Await the PDUFA date of November 14, 2026, for the BLA submission of ivonescimab in NSCLC.
• Anticipate PFS and interim OS data readouts for HARMONi-3 (squamous NSCLC) in 1H26.
• Anticipate PFS data readout for HARMONi-3 (non-squamous NSCLC) in 1H27.

Key Dates

Recommendation

The presented data, particularly the statistically significant overall survival benefit in first-line NSCLC and the high response rates in mCRC, represent a substantial de-risking event for ivonescimab. The drug's potential as a first-in-class PD-1/VEGF bispecific antibody with a favorable safety profile positions it for significant market penetration, justifying a strong buy recommendation.

Keywords

ivonescimab, Summit Therapeutics, colorectal cancer, metastatic colorectal cancer, mCRC, non-small cell lung cancer, NSCLC, oncology